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NEW RESEARCHCombined Stimulant and Guanfacine Administration in
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VOLUMJames T. McCracken, MD, James J. McGough, MD, Sandra K. Loo, PhD, Jennifer Levitt, MD,
Melissa Del’Homme, PhD, Jennifer Cowen, PhD, Alexandra Sturm, PhD, Fiona Whelan, MS,
Gerhard Hellemann, PhD, Catherine Sugar, PhD, Robert M. Bilder, PhDObjective: Because models of attention-deﬁcit/
hyperactivity disorder (ADHD) therapeutics emphasize
beneﬁts of both enhanced dopaminergic and noradren-
ergic signaling, strategies to enhance D1 and a2A agonism
may yield enhanced clinical and cognitive responses. This
study tested the hypothesis that combined effects of a
dopamine and noradrenergic agonist, d-methylphenidate
extended-release (DMPH) with guanfacine (GUAN), an
a2A receptor agonist, would be clinically superior to either
monotherapy and would have equal tolerability.
Method: An 8-week, double-blind, 3-arm, comparative
trial randomized 7- to 14-year-olds with DSM-IV ADHD
to GUAN (13 mg/day), DMPH (520 mg/day), or a
combination (COMB) with ﬁxed-ﬂexible dosing. Outcome
measures were the ADHD Rating Scale IV (ADHD-RS-IV)
and the Clinical Global ImpressionImprovement (CGI-I)
scale. Data on adverse events and safety measures were
obtained.
Results: A total of 207 participants were randomized
and received drug. Analyses showed signiﬁcant treat-
ment group main effects for ADHD-RS-IV ADHD total
(p ¼ .0001) and inattentive symptoms (p ¼ .0001). COMB
demonstrated small but consistently greater reductions inClinical guidance is available at the end of this article.
Supplemental material cited in this article is available online.
OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
E 55 NUMBER 8 AUGUST 2016ADHD-RS-IV Inattentive subscale scores versus mono-
therapies (DMPH: p ¼ .05; f2 ¼ .02; and GUAN: p ¼ .02;
f2 ¼ .02), and was associated with a greater positive
response rate by CGI-I (p¼ .01). No serious cardiovascular
events occurred. Sedation, somnolence, lethargy, and fa-
tigue were greater in both guanfacine groups. All treat-
ments were well tolerated.
Conclusion: COMB showed consistent evidence of clin-
ical beneﬁts over monotherapies, possibly reﬂecting ad-
vantages of greater combined dopaminergic and a2A
agonism. Adverse events were generally mild to moder-
ate, and COMB treatment showed no differences in safety
or tolerability.
Clinical trial registration information: Single Versus
Combination Medication Treatment for Children With
Attention Deﬁcit Hyperactivity Disorder (Project1);
http://clinicaltrials.gov/; NCT00429273.
Key words: ADHD, children, guanfacine, methylpheni-
date, alpha2A
J Am Acad Child Adolesc Psychiatry 2016;55(8):657–666.ttention-deﬁcit/hyperactivity disorder (ADHD) is
the most commonly diagnosed mental disorder inA children, with a prevalence of 9%1; some 2.8 million
children in the United States receive psychostimulant
medication. ADHD shows diagnostic persistence (30%
70%) and morbidity into adulthood.2-4 ADHD outcomes
vary regardless of treatment: when persistent, ADHD affects
nearly all domains of functioning.3-6
Current ADHD medications, including psychostimulants
and guanfacine, robustly ameliorate ADHD symptoms in
the short term, with “responder” rates of 65% to 75%7,8 and
50% to 67.5%9-11 for stimulants and guanfacine, respec-
tively.12,13 Despite symptom reduction with monotherapies,there is little evidence to show that medications change
long-term trajectories of either symptoms or academic, psy-
chiatric, and social outcomes,14-19 although some acute17,20
and follow-up studies ﬁnd modest academic gains.21,22 The
discordance between symptom reduction from standard
treatments and continued impaired functioning long term
highlights the importance of identifying treatments that
better remediate proximal causes of negative outcomes.
Closer examination of ADHD monotherapy outcomes
reveals likely explanations for lack of disorder-modifying
effects. Besides the substantial number of nonresponders
and those who experience intolerable side effects, too few
patients experience “normalization” of ADHD with mono-
therapy.7,23 Normalization rates vary by domain: symp-
tomatic normalization with methylphenidate was observed
in 58% of children with ADHD in one report, 50% of par-
ticipants showed normalization of inattention, yet only 30%
demonstrated normalized academic efﬁciency.20 In the
Multimodal Treatment of ADHD study (MTA), even with
rigorous dose optimization, only 56% achieved symptomaticwww.jaacap.org 657
McCRACKEN et al.remission.24 Such ﬁndings contrast with recommendations
that remission of ADHD should be a goal.7
Recommendations for greater symptom reduction
spring from observations that residual symptoms are
associated with negative outcomes in school, social, and
emotional domains.2,23 A variety of clinical and contextual
factors inﬂuence outcomes, but, relevant to medication
treatment, cognitive functioning has also emerged as
important.25-28
Medication effects on cognitive control, encompassing
working memory (WM) and inhibitory control, are crucial to
consider, given the robust association of their deﬁcits with
ADHD,29,30 as well as inﬂuence on outcomes.25-28 Effects of
stimulants on cognition in ADHD are more variable than
symptom reduction.31-33 Data on cognitive effects of guan-
facine monotherapy in pediatric ADHD34 are sparse; no data
are available on cognitive effects of combined stimulant plus
a agonists.
Neurochemical models of ADHD and its treatment
emphasize catecholaminergic inﬂuences onprefrontal cortical
functioning (PFC).35,36 Stimulants are thought to improvePFC
function via increasing endogenous dopamine (DA) stimu-
lation, especially at D1 receptors,37 and increasing norepi-
nephrine (NE) at a2-adrenergic receptors.
37 Guanfacine
appears to exert beneﬁcial PFC effects through selective
postsynaptic a2A agonism.
38 Agonists at both D1 and a2A re-
ceptors produce inverted U-shaped WM functions.38-40 In
somemodels, optimal DA stimulation of cortical D1 receptors
paired with D2 inhibition of nigral-striatal activity are theo-
rized to underlie stimulant beneﬁts,41 augmented by norad-
renergic effects on reaction time and switching deﬁcits.42
Taken together, these models suggest that treatments with
optimized D1 and a2A agonism may yield superior effects on
clinical and cognitive targets.36
The purpose of this study was to test the hypothesis that
clinical and cognitive responses in ADHD to combined
treatment robustly enhancing both DA and NE would be
superior to monotherapies.35,40 Therefore, we assessed the
relative efﬁcacy of a psychostimulant (d-methylphenidate
extended-release [DMPH]) versus an a2A agonist, guanfacine
(GUAN), versus their combination (COMB) on ADHD
symptoms, clinical response rates, and cognitive outcomes in
an 8-week randomized, blinded, comparative trial, using a
hybrid within-/between-subjects design with sequential
addition of medications to maximize power. Effects on
cognition and electroencephalography (EEG) correlates are
presented in separate reports.43,44METHOD
Participants
The sample consisted of children and adolescents 7 to 14 years of age
who were diagnosed with ADHD. All participants were enrolled in
the Translational Research to Enhance Cognitive Control (TRECC)
ADHD study (ClinicalTrials.gov Identiﬁer: NCT00429273). Partici-
pants were recruited from clinic referrals, radio and newspaper
advertisements, community organizations (Children and Adults
with ADHD [CHADD]; www.chadd.org), local schools, and pri-
mary care physicians. Parents and participants provided written658 www.jaacap.orginformed permission and assent, respectively. All study procedures
were approved by the University of California, Los Angeles (UCLA)
institutional review board and were overseen by a data safety and
monitoring board.
Inclusion criteria were as follows: male or female individuals 7 to
14 years of age; DSM-IV ADHD (any subtype) diagnosed by semi-
structured diagnostic interview (Kiddie-Schedule for Affective
Disorders and SchizophreniaLPL [K-SADS-PL])45 and clinical
interview; and Clinical Global Impression—Severity (CGI-S)
score 4 for ADHD.
Exclusion criteria were as follows: autistic disorder, chronic tic
disorder, psychosis, bipolar disorder, or structural heart defects;
current major depression or panic disorder; systolic or diastolic
blood pressure >95th or <5th percentile for age and body mass
index (BMI); medical condition contraindicating stimulants or a
agonists; and need for chronic use of other central nervous system
(CNS) medications.
Study Design
The study was an 8-week double-blind, randomized, controlled trial
with 4 treatment conditions: placebo only, DMPH: d-methylpheni-
date extended-release (5L20 mg/day) þ placebo; GUAN: guanfa-
cine (1L3 mg/day) þ placebo; and COMB: treated combination of
guanfacine and DMPH. We used a hybrid within-between subject
experimental design in which each participant was assessed
sequentially in at least 2 different treatment conditions, and maxi-
mally to 3 of the 4 treatment conditions. Because of ethical and
practical considerations, the order of the treatment conditions was
not counterbalanced; instead, participants were randomized in a
1:1:1 ratio to 3 different treatment sequences covering the
periods baseline, weeks 1 to 4, and weeks 5 to 8 as follows:
sequence 1: PlaceboePlacebo þ DMPH
sequence 2: GuanGuan þ Placebo
sequence 3: GuanGuan þ DMPH
Thus, during the ﬁrst 4 weeks, two-thirds of the participants
received guanfacine (sequences 2 and 3) whereas one-third of the
participants were given a placebo (sequence 1); beginning in week 5,
participants initially given guanfacine added either DMPH
(sequence 3) or a placebo (sequence 2) to their regimen, whereas
those who started on placebo added DMPH (sequence 1).
Guanfacine (immediate-release form, as guanfacine extended
release was not available at beginning of study) and placebo dosing
mirrored titration schedules in prior trials.9,10 Dosing clinicians were
blinded to group assignment. Initial dosing was 1 capsule (0.5 mg or
placebo) twice daily for week 1; week 2, the dose increased to 1 mg
twice daily as tolerated; and week 3, doses increased to 1.5 mg twice
daily as tolerated. If Clinical Global ImpressionLImprovement
(CGI-I) ratings were either 1 or 2 (much improved or very much
improved), no dose increase was made; no dose increases were
allowed after week 3. Optimal guanfacine dose was determined by
CGI-I ratings, ADHDRating ScaleLVersion IV (ADHD-RS-IV)46 and
side effects at end of week 3, by consensus agreement of 2 indepen-
dent study clinicians, and was deﬁned as the lowest dose providing
maximal improvement while minimizing adverse events. A mini-
mum total daily dose of 1.0 mg was required for continuation.
DMPH (dual-beaded, extended-release formulation) dosing fol-
lowed published experience.47 Two dose schedules were based upon
baseline weight. Participants <25 kg received 1 capsule (5 mg or
placebo) of DMPH once daily for week 5; week 6 the dose was
increased to 10 mg DMPH daily; and week 7 the dose was increased
to 15 mg daily. For participants 25 kg, DMPH began with 10 mg
DMPH once daily; week 6 it increased to 15 mg daily; and week 7 it
increased to 20 mg daily. No dose increases were allowed after week
7. Low, medium, and high stimulant doses were assessed weekly forJOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
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STIMULANT/GUANFACINE FOR ADHD: CLINICALbehavioral response and tolerability to determine the “optimal”
DMPH according to the identical process described above.
We note that this differs by degree from a traditional 3-arm lon-
gitudinal designwith each arm receiving a speciﬁc treatment over the
entire study period, but this is a hybrid sequential within-/between-
subjects design. This design arose from the clinical and ethical need to
keep trial length and placebo-only exposure to aminimum.However,
the within-subject component also increases statistical power. More-
over, because prior reports show maximal beneﬁt from both treat-
ments within 3 to 4 weeks, this design allows us to compare the
medication conditions (placebo, GUAN, DMPH, and COMB) by
combining all participants and time points for which that condition
occurred, after adjusting for overall drift.Outcome Measures
We used ADHD behavioral ratings from independent evaluators
and parents, vital signs, electrocardiograms, adverse eventFIGURE 1 Disposition (Consolidated Standards of Reporting Tria
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including repeat electroencephalograms.44
Symptom Assessments. A blinded clinician without knowledge of
adverse events completed the CGI-S and ADHD-RS-IV at baseline
and at the end of each within-subject condition or last visit based on
parent, participant, and other available data. A treating clinician
completed the CGI-I at baseline and each week.
Side Effect Assessments. Side effects were measured via a struc-
tured instrument, using a modiﬁcation of the Physical Symptoms
Checklist48 and open-ended clinician inquiry.
Clinical Endpoints. The primary clinical efﬁcacy variables for
treatment were the 3 scores from the ADHD-RS-IV (Inattentive and
Hyperactive-Impulsive subscales, and total score) and the CGI-I.
Our primary deﬁnition of treatment response was CGI-I 1 or 2
(“very much improved” or “much improved”) versus nonre-
sponder. We also examined a second response criterion, adding a
reduction in ADHD-RS-IV total scores of 30% from baseline to
week 8 to the initial CGI-I criterion.24ls [CONSORT]) for all enrolled study participants. Note:
nidate extended-release; GUAN ¼ guanfacine.
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McCRACKEN et al.Statistical Analyses
All analyses were conducted in SAS 9.2. For the longitudinal models,
we used Proc Mixed, with a compound symmetric covariance
structure to account for repeated measurements within participants.
The data were modeled with treatment condition (DMPH, GUAN,
COMB, or untreated/placebo [UN/PBO]) and time as within-subject
effects, and age as a participant-level covariate. Note that in this
model, the placebo effect is confounded with the time effect and
cannot be estimated separately, as the change from baseline to week 4
for participants in sequence 1 (the group with multiple measure-
ments in the untreated/placebo condition) could be equally
explained by effects of retesting or placebo effects. The pairwise
comparisons between the different treatment conditions are 1 degree
of freedom contrasts of the condition effect in this model. All tests
used a 2-sided signiﬁcance level of a ¼ .05. For the pairwise com-
parisons of the treatment conditions, we report Cohen’s f2 effect size
difference, which is recommended for analyses involving F tests or
analysis of variance models.49 Small, medium, and large f2 values are
traditionally deﬁned as 0.02, 0.15, and 0.35, respectively.
For the analyses of treatment response, we used Pearson c2 tests,
comparing the rates in the 3 treatment sequences (ending with
GUAN alone, DMPH alone, or COMB), along with number needed
to treat (NNT)50 as the effect size. For NNT, small, medium, and
large effects are deﬁned as 9, 4, and 2, respectively.50RESULTS
Demographics and Disposition
A total of 212 participants were deemed eligible and ran-
domized (Figure 1). Of those, 207 received at least one doseTABLE 1 Participant Demographics by Assigned Treatment Group
GUAN (n ¼ 68) D
Age, y, mean (SD) 10.1 (2.1)
Sex, n (%)
Male 45 (66.2)
Race/ethnicity, n (%)
White 51 (75.0)
African American 7 (10.3)
Asian, Paciﬁc Islander 7 (10.3)
Other 3 (4.4)
Hispanic 16 (23.5)
Weight, kg, mean (SD) 39.8 (17.5)
Height, cm, mean (SD) 140.6 (14.4)
Full Scale IQ 102.6 (14.2)
ADHD subtype, n (%)
Inattentive 28 (41)
Hyperactive/Impulsive 1 (2)
Combined 38 (56)
ADHD-RS-IV baseline, mean (SD)
Inattentive 21.3 (0.7)
Hyperactive/Impulsive 15.9 (0.8)
Combined 37.1 (1.2)
Comorbidity, n (%)
ODD 27 (40)
Note: ADHD ¼ attention-deficit/hyperactivity disorder; ADHD-RS-IV ¼ ADHD Rating S
GUAN ¼ guanfacine; ODD ¼ oppositional defiant disorder.
aForms efficacy and safety samples. No significant differences between groups (al
660 www.jaacap.orgof study drug and form the safety and intent-to-treat sam-
ples (Table 1). Mean age was 10.0 (SD  2.1 years), and 142
(68%) were male. No signiﬁcant group differences were
found for age, IQ, sex, ADHD subtype, height, weight,
percentage of oppositional deﬁant disorder (ODD) comor-
bidity, or baseline ADHD-RS-IV scores. Mean ﬁnal (week 8)
daily doses of DMPH were 16.0 ( 3.9) mg for DMPH-only
and 15.1 ( 4.8) mg for COMB. Mean ﬁnal daily doses
of guanfacine were 2.2 ( 0.7) mg for GUAN-only and 2.4
( 0.6) mg for COMB. Mean mg/kg daily doses of guanfa-
cine were 0.06 ( 0.03) mg/kg/d for both guanfacine
groups. Exposures to the 2 treatments were comparable to
prior studies.9-11,20,32,51,52 In all, 87.8% of the randomized
sample completed the 8-week trial.
Efﬁcacy Measures
Results of the mixed model analyses are presented in
Figure 2A to 2C and Table 2 (additional symptom data in
Table S1, available online). There was strong agreement
between the raw means and model estimates, suggesting
excellent model ﬁt. The corresponding ﬁgures show the
changes in estimated means by treatment condition from
baseline and over time. All participants showed improve-
ment in their ADHD-RS-IV total score over time, indepen-
dent of treatment condition as demonstrated by the
signiﬁcant effect for visit (F ¼ 18.90, df ¼ 1, p < .0001), and
signiﬁcant effects of treatment condition (F ¼ 10.14, df ¼ 3,
p < .0001). Examination of the ADHD-RS-IV Inattentive
subscale scores also showed improvements with signiﬁcanta
MPH (n ¼ 69) COMB (n ¼ 70) Total (n ¼ 207)
10.1 (2.0) 9.9 (2.2) 10.0 (2.1)
46 (66.7) 51 (72.9) 142 (68)
51 (73.9) 41 (58.6) 143 (69)
10 (14.5) 19 (27.1) 36 (17)
4 (5.8) 5 (7.1) 16 (8)
4 (5.8) 5 (7.1) 12 (6)
10 (14.5) 18 (25.6) 44 (21.3)
41.6 (16.2) 40.0 (16.7) 40.5 (16.7)
142.9 (13.6) 141.2 (14.4) 141.6 (14.1)
101.5 (13.3) 102.9 (13.0) 102.4 (13.5)
33 (48) 31 (44) 92 (44)
2 (3) 2 (3) 5 (2)
32 (46) 35 (50) 105 (51)
21.2 (0.7) 20.3 (0.7)
17.2 (0.8) 14.7 (0.8)
35.3 (1.2) 35.1 (1.2)
24 (35) 17 (24) 68 (33)
cale IV; COMB ¼ combination; DMPH ¼ d-methylphenidate extended-release;
l p >.05).
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FIGURE 2 (A) Changes in least-squares (LS) means for Attention-Deficit/Hyperactivity Disorder (ADHD) Rating Scale IV (ADHD-
RS-IV) Inattentive subscale scores from baseline to week 8 for the 3 randomized treatment groups. (B) Changes in least-squares
means for ADHD-RS-IV Total scores from baseline to week 8 for the 3 randomized treatment groups. (C) Least-squares mean ADHD-
RS-IV Inattention subscale scores by current treatment condition from baseline to week 8. Note: COMB ¼ combination; DMPH ¼
d-methylphenidate extended-release; GUAN ¼ guanfacine.
STIMULANT/GUANFACINE FOR ADHD: CLINICALeffects for visit (F ¼ 14.20, df ¼ 1, p ¼ .0002) and differences
by treatment condition (F ¼ 11.28, df ¼ 3, p < .0001). Similar
effects were seen in ADHD-RS-IV Hyperactive-Impulsive
subscale scores for visit (F ¼ 12.42, df ¼ 1, p ¼ .0005) and for
treatment condition (F ¼ 4.09, df ¼ 3, p ¼ .0069).
To examine the speciﬁc nature of the treatment effects, 1
degree of freedom contrasts were used to compare each pair
of medication conditions (Table 2). COMB showed superi-
ority for total ADHD-RS-IV total score versus GUAN
(t ¼ 1.99, p ¼ .049, 2-tailed; f2 ¼ 0.02), but did not differ
statistically from DMPH (t ¼ 1.84, p ¼ .066; f2 ¼ 0.01). For
ADHD-RS-IV Inattentive subscale scores, COMB again
showed superiority over GUAN (t ¼ 2.28, p ¼ .02, 2-tailed;
f2 ¼ 0.02) as well as a trend of greater improvement
than DMPH (t ¼ 1.94, p ¼ .05; f2 ¼ 0.02); both differences
yielded small but consistent effect size estimates. Examina-
tion of estimated marginal means shows that compared
to the initial placebo-only condition and controlling for
time, ADHD-RS-IV Total scores are substantially lower
in the GUAN (46%), DMPH (44%), and COMB (51%)
conditions.
There were signiﬁcant differences in treatment response
(CGI-I “very much improved” or “much improved”) for the
3 treatment sequences, with rates of 81% for sequence 1
(ending with DMPH alone), 69% for sequence 2 (ending with
GUAN alone), and 91% for sequence 3 (COMB) (c2 ¼ 8.55,
df ¼ 2, p ¼ .01) (NNT 4.6: COMB versus GUAN; NNT 10:JOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
VOLUME 55 NUMBER 8 AUGUST 2016COMB versus DMPH). Using the combined deﬁnition of
treatment response based on CGI-I and end-of-trial ADHD-
RS-IV total scores gave rates of 62%, 63%, and 75%,
respectively (NNT 8.5: COMB versus GUAN; NNT 7.5:
COMB versus DMPH).
Safety Assessments
Treatment-emergent adverse events (TEAEs) with a fre-
quency of 10% occurring at any time are shown in Table 3.
Overall rates for any TEAE (mild, moderate, and severe)
were high but did not differ among groups. No serious AEs
occurred during the trial. Most TEAEs were mild to mod-
erate in severity. Discontinuation at any time due to TEAEs
was low and equivalent across groups: 1.5% (1/68) in
GUAN, 1.5% (1/69) in DMPH, and 2.9% (2/70) in COMB.
Discontinuation at any time because of lack of efﬁcacy or
clinical worsening was uncommon, with 2.9% (2/68) in
GUAN, none in DMPH, and 1.4% (1/70) in COMB dis-
continuing because of these outcomes.
Cardiovascular indices at week 8 showed small changes
from baseline. Mean sitting pulse rate declined by4.1 (12.6)
beats/min for GUAN, increased by 3.6 (15.7) beats/min for
DMPH, and increased by 4.6 (16.7) beats/min for COMB.
Mean systolic blood pressure declined by 2.2 (13.8) mm Hg
for GUAN, increased by 7.3 (11.5) mm Hg for DMPH, and
increased by 3.5 (14.1) mm Hg for COMB. Mean diastolic
blood pressure declined by 3.8 (11.4) mm Hg for GUAN,www.jaacap.org 661
TABLE 2 Pairwise Comparisons of Least-Squares Mean
Attention-Deficit/Hyperactivity Disorder Rating Scale IV
(ADHD-RS-IV) Scores by Assigned Treatment Conditions
ADHD-RS
Total Score
Estimated
Difference F p Value
Effect
Size f2
COMB vs. Placebo 10.66  1.99 28.68 <.0001 0.12
COMB vs. GUAN 2.67  1.35 3.93 .049 0.02
COMB vs. DMPH 2.89  1.56 3.44 .065 0.01
GUAN vs. DMPH 0.21  1.31 0.03 .87 0.0001
GUAN vs. Placebo 7.99  1.22 42.43 <.0001 0.18
DMPH vs. Placebo 7.77  1.70 20.98 <.0001 0.01
Inattention Subscale
Estimated
Difference F p Value
Effect
Size f2
COMB vs. Placebo 5.89  1.15 26.08 <.0001 0.11
COMB vs. GUAN 1.79  0.79 5.21 .023 0.02
COMB vs. DMPH 1.74  0.90 3.75 .054 0.02
GUAN vs. DMPH 0.049  0.76 0 .95 0
GUAN vs. Placebo 4.10  0.71 33.26 <.0001 0.14
DMPH vs. Placebo 4.14  0.99 17.41 <.0001 0.01
Hyperactive-
Impulsive Subscale
Estimated
Difference F p Value
Effect
Size f2
COMB vs. Placebo 5.10  1.12 20.75 <.0001 0.09
COMB vs. GUAN 1.10  0.75 2.15 .14 0.01
COMB vs. DMPH 1.37  0.87 2.45 .12 0.01
GUAN vs. DMPH 0.27  0.72 0.14 .71 0.01
GUAN vs. Placebo 4.0  0.69 33.59 <.0001 0.14
DMPH vs. Placebo 3.73  0.92 16.32 <.0001 0.01
Note: COMB ¼ combination; DMPH ¼ d-methylphenidate extended-release;
GUAN ¼ guanfacine.
McCRACKEN et al.increased by 5.8 (10.4) mm Hg for DMPH, and increased by
3.7 (9.9) mmHg for COMB. Changes in the QTcBwereminor,
with a decrease of 2.7 (16.4) milliseconds for GUAN, an
increase of 9.9 (22.5) milliseconds in the DMPH group, and a
decrease of 4.4 (20.8) milliseconds for COMB. No partici-
pant demonstrated a QTcB interval of 500 milliseconds or
an increase of >60 milliseconds during the trial. No clinically
signiﬁcant laboratory ﬁndings were observed.DISCUSSION
This study represents a novel test of a theory-driven com-
bination of 2 drugs with distinct mechanisms of action for
ADHD versus standard monotherapies. It is the ﬁrst report,
to our knowledge, to directly test the beneﬁts of the com-
bination to monotherapies in a sample not ascertained to be
partially stimulant responsive.51,52 Results from this
comparative trial provide modest but cogent evidence for
the clinical superiority of the combination treatment of a
stimulant and an a2A agonist for the treatment of ADHD. On
clinical global measures of response and ADHD symptoms
(especially inattentive symptoms), combination treatment in
most comparisons showed additional beneﬁts without any
evidence of diminished tolerability, safety concerns, or
increased side effect burden. The symptomatic beneﬁts of662 www.jaacap.orgcombination treatment could yield improvements in longer-
term outcomes, given the role of residual ADHD symptoms
on functioning.2,23 Results with this combination, based on
neurochemical models of ADHD, add support for the “dual”
model of the importance of optimized dopaminergic and
noradrenergic effects in ADHD therapy.35
However, a deeper discussion of the effects of combina-
tion treatment is needed to support a determination of
“superiority” over monotherapies. These comparisons
focus solely on acute clinical effects; our initial interest in
combination was its hypothesized superiority for both clin-
ical and cognitive outcomes. A more comprehensive com-
parison admittedly requires joint consideration of broader
effects, and at an individual level. The EEG effects suggest
COMB exhibited greater normalizing effects than the mon-
otherapies, by decreasing theta and increasing beta fre-
quency band power.44 That said, on clinical outcomes alone,
in keeping with our hypotheses, COMB showed small but
consistently greater reductions in ADHD-RS-IV Inattentive
subscale scores to both monotherapies, and surpassed
GUAN on ADHD-RS-IV total score comparison, again
showing consistent, albeit small, effect size differences on
these dimensional endpoints. Despite the small separation
on symptom scores in comparison to GUAN, COMB
emerged robustly superior by a 22% difference to GUAN on
responder comparisons (NNT ¼ 4.6), a moderate effect, with
DMPH intermediate (NNT ¼ 10). Importantly, tolerability
did not differ by condition.
Can these small effect size differences be clinically sig-
niﬁcant? As pointed out by Kraemer and Kupfer,50 treat-
ments with equivalent risk and burden may be deemed
clinically superior even with effect size differences far less
than the small to medium effects that we have documented
for COMB versus both monotherapies. For comparison, our
approximate 3-point least-squares mean difference between
COMB and the monotherapies is equivalent to the 3-point
difference reported in the MTA between medication man-
agement versus behavior treatment groups on teacher
Swanson, Nolan, and Pelham (SNAP) total scores.
Supporting a role for a2A modulation in ADHD treat-
ment, our ﬁndings add to extant data on the efﬁcacy of an
a2A agonist, guanfacine. Guanfacine has emerged as
approved ADHD monotherapy for children and adolescents
with ADHD with moderate efﬁcacy.9-11 Another less selec-
tive a2 agonist, clonidine, has beneﬁts on ADHD symptoms
from controlled trials in children with ADHD with53 and
without54 tic disorders, and as an adjunctive treatment in
children with ADHD partially responsive to stimulants.55,56
Not surprisingly, guanfacine alone showed efﬁcacy in
reducing total ADHD symptoms (ADHD-RS total 46%
from baseline) in our trial, with a very good clinical response
rate (69% improved by CGI-I), nearly identical to a ﬂexibly
dosed monotherapy trial in adolescents (68%).11
The 2 pivotal trials of guanfacine extended release for
ADHD using a randomized, ﬁxed-dose design also showed
remarkably comparable reductions in total ADHD symptom
reduction by ADHD-RS (45% and 49%), with global
responder rates of 54% to 56% and 50% to 56%.9,10 Overall,
our efﬁcacy data with guanfacine appear to be on par withJOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
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TABLE 3 All Treatment-Emergent Adverse Events Occurring During the Double-Blind Phase by Randomized Treatment Groups
Adverse Event, n (%) COMB (n ¼ 70) DMPH (n ¼ 69) GUAN (n ¼ 68) p Value
Any adverse event 69 (98.6) 66 (95.7) 66 (97.1) .93
Neuropsychiatric disorders
Headache 23 (32.9) 23 (33.3) 34 (50.0) .10
Irritability 18 (25.7) 12 (17.4) 15 (22.1) .49
Sedation 16 (22.9) 4 (5.8) 12 (17.6) .02
Somnolence 15 (21.4) 3 (4.3) 16 (23.5) .01
Affect lability 8 (11.4) 14 (20.3) 7 (10.3) .16
Gastrointestinal disorders
Abdominal pain 16 (22.9) 18 (26.1) 19 (27.9) .83
Abdominal pain upper 10 (14.3) 10 (14.5) 11 (16.2) .97
Sleep disturbance
Insomnia 24 (34.3) 20 (29.0) 18 (26.5) .53
Metabolism and nutrition disorders
Decreased appetite 25 (35.7) 31 (44.9) 15 (22.1) .01
General disorders
Lethargy 16 (22.9) 9 (13.0) 23 (33.8) .02
Fatigue 12 (17.1) 5 (7.2) 22 (32.4) .001
Vascular disorders
Dizziness 7 (10.0) 6 (8.7) 8 (11.8) .87
Note: COMB ¼ combination; DMPH ¼ d-methylphenidate extended-release; GUAN ¼ guanfacine.
STIMULANT/GUANFACINE FOR ADHD: CLINICALthe monotherapy guanfacine extended release trials, with
our greater global response rates likely reﬂecting our
younger sample and our use of a ﬁxed-ﬂexible titration
scheme, optimizing on clinical response. Notably, the one
pivotal trial of guanfacine extended release that reported
analyses by ADHD subtype found that those participants
with ADHD Inattentive subtype (26% of all participants) in
their sample showed no statistically signiﬁcant beneﬁt of
guanfacine.10 Such a ﬁnding suggests that guanfacine addi-
tion in our sample, with its higher proportion (44%) of
participants with inattentive ADHD, would be predicted to
yield less additive beneﬁt. In that light, our observed COMB
effects could represent an underestimate of the beneﬁcial
effects of COMB in individuals with combined ADHD, and
could also support our focus on change in ADHD-RS-IV
Inattentive symptoms where COMB showed greater sepa-
ration from both monotherapies.
DMPH monotherapy showed expected clinical beneﬁts
with moderate reductions in ADHD symptoms and an in-
termediate clinical global response rate of 81% between the 2
comparison arms. Our observed responder rate is compa-
rable to similar trials,12 including the 79% responder rate in a
comparative stimulant trial.57 Yet the addition of a selective
a2A to DMPH boosted comparative efﬁcacy versus DMPH
on most measures. Pairwise comparisons of DMPH to
the COMB condition found COMB to be statistically
superior to DMPH on ADHD-RS-IV inattentive symptoms
and global response rates with small to moderate effect
size differences.
Although overall response rates by CGI-I in our trial
were high, examination of the other commonly applied
combined categorical þ dimensional response rate (CGI-I 1
or 2, “very much” or “much” improved, and >30% reduc-
tion in ADHD-RS-IV from baseline) is informative. BothJOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
VOLUME 55 NUMBER 8 AUGUST 2016monotherapies yielded expected improvement rates of
62% and 63%, with COMB boosting response to 75%
(NNT 7.5 and 8.5, versus DMPH and GUAN, respectively).
The impact of these differences in “excellent” responses,
although admittedly small to moderate effects, need to be
examined over time to discern their clinical signiﬁcance.
However, at the very least, they underscore the continued
challenge in ADHD therapeutics to achieve more robust,
trajectory-changing outcomes.
The clinical implications of our results suggest that
combination of DMPH and GUAN over 8 weeks is associ-
ated with substantial clinical beneﬁts on ADHD symptoms
in the short term, and is more successful at approaching
contemporary goals for ADHD treatment. Our data, taken
together with data from positive combined trials showing
beneﬁcial effects of guanfacine and clonidine addition to
stimulants in ADHD partial responders,51,52 and combined
treatment in children with ADHD and chronic tic disor-
ders,53 provide solid evidence for the clinical beneﬁts of
combined stimulant and a-adrenergic agonist treatment.
Our results also support the acceptable safety proﬁle of
COMB treatment. Adverse events observed were consistent
with the literature for both monotherapies.47,58,59 Guanfa-
cine, as a monotherapy and as COMB, was associated with a
greater frequency of sedation, fatigue, and somnolence. Most
such adverse events were mild or moderate in severity, and
very few participants discontinued due to any adverse
events. There was no signal that COMB was associated with
a greater adverse event burden or with any unique, serious
adverse events.
The cardiovascular effects of the treatments were also
consistent with the literature. Taken together with the largest
extant studies of stimulants plus an a2A agonist, available
data do not show evidence for added risk of thiswww.jaacap.org 663
McCRACKEN et al.combination in the treatment of healthy children and ado-
lescents, although expected effects of bradycardia and hy-
potension have been observed,51-53,58,59 and clinical
recommendations should include mention of risk of syncope
with a2A agonists. Therefore, the acute safety database for
combination stimulant plus an a2 agonist and initial longer-
term data58,59 argues for acceptable safety and very good
tolerability.
Our study ﬁndings have several implications for ADHD
biology. The primary hypothesis behind the COMB strategy
rested on the consistent observations that cognitive control
functions, especially WM and inhibitory control, are modu-
lated by dopamine and noradrenaline.35-37 Theories of
ADHD continue to emphasize deﬁcient or “imbalanced”
dopamine systems,36,60 and possibly noradrenergic dysre-
gulation.35 Although the core pathophysiology of ADHD is
unknown, such catecholamine abnormalities are thought to
underlie ADHD differences in PFC function, reward pro-
cessing, and motivation. Arnsten and Pliszka have advanced
the notion that DA and NE postsynaptic effects, at optimal
levels, exert differing and complementary positive inﬂuences
on information processing in the PFC.35 Our data on the
effects of COMB treatment on clinical outcomes, especially
on inattentive ADHD symptoms, appear to support the
above models of ADHD and WM biology and the effects of
catecholamine agonists. However, these data do not conﬁrm
a dopamine or noradrenergic ADHD “deﬁcit,” and we
acknowledge that stimulants also have noradrenergic effects,
complicating interpretation. Furthermore, the absence of
pro-cognitive effects of guanfacine43 raises the possibilityClinical Guidance
 A comparison of combination treatment with guanfacine
and dexmethylphenidate versus monotherapy with
guanfacine or dexmethylphenidate in children and
adolescents with ADHD showed that combination
treatment was associated with greater improvement,
particularly by categorical ratings, during the 8-week trial.
 Beneﬁts of combined treatment may extend beyond
children with ADHD who are partially responsive to
stimulant monotherapy, based on this study.
 Combined treatment with an a agonist þ stimulant is one
approach that may be more likely to achieve the goal of
“remission” in ADHD therapy.
 Regular monitoring of cardiovascular parameters and
warning parents about risks of syncope and dehydration is
recommended when treating with both a stimulant and an
a agonist, but available data suggest no signiﬁcant
changes in overall safety.
 Combination treatment is generally well tolerated by most
children and adolescents.
664 www.jaacap.orgthat this drug may also be acting presynaptically, or insuf-
ﬁciently engaging the target of prefrontal a2A receptors.
Although there are many strengths of the study, including
blinded comparison of 3 treatments, an ADHD sample not
selected for stimulant refractoriness, and ﬂexible dosing to
optimize beneﬁt, our ﬁndings have several limitations. Larger
group sizes would have enabled more conclusive tests of
treatment differences. Our study design began with guanfa-
cine ﬁrst, with the addition of a stimulant second, which may
yield differences in comparison to those study designs adding
guanfacine to ongoing stimulants, and, like any sequential
design, may blur the timing of individual treatment effects
when combined. Furthermore, drug dosage was optimized
by clinical response rather than cognitive response or
biomarker, which might have better separated the treat-
ments. Finally, we note that CGI-I ratings were made by
treating clinicians, who were privy to side effect information.
In summary, results from our study suggest modest but
consistent additional beneﬁt from a carefully applied com-
bination of a psychostimulant with a selective a2A agonist,
guanfacine, on ADHD symptoms and global clinical re-
sponses. Our ﬁndings should also serve to encourage further
research to identify a range of treatment strategies using
other possible approaches to successfully improve the long-
term trajectory of ADHD. &
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TABLE S1 Attention-Deficit/Hyperactivity Disorder (ADHD) Rating Scale IV (ADHD-RS-IV) Estimated and Actual Mean Scores at
Baseline, Week 4, and Week 8
Total Estimated and Actual Mean Scores
Assigned
Group Estimated/Observed Current Med
Baseline
Mean  SE Current Med
Wk 4
Mean  SE Current Med
Wk 8
Mean  SE
COMB Est means Placebo 36.2  0.6 Guanfacine 24.0  0.8 Comb 17.9  1.3
Obs means Placebo 35.6  1.2 Guanfacine 25.3  1.3 Comb 17.9  1.3
GUAN Est means Placebo 36.2  0.6 Guanfacine 24.0  0.8 Guanfacine 19.5  1.0
Obs means Placebo 36.8  1.1 Guanfacine 23.5  1.4 Guanfacine 18.7  1.5
DMPH Est means Placebo 36.2  0.6 Placebo 31.7  1.0 DMPH 20.4  1.3
Obs means Placebo 35.6  1.0 Placebo 31.7  1.0 DMPH 20.4  1.0
Inattentive Subscale Estimated and Actual Mean Scores
Assigned
Group Estimated/Observed Current Med
Baseline
Mean  SE Current Med
Wk 4
Mean  SE Current Med
Wk 8
Mean  SE
COMB Est means Placebo 21.2  0.4 Guanfacine 14.5  0.4 Comb 10.7  0.7
Obs means Placebo 20.4  0.6 Guanfacine 15.2  0.8 Comb 10.7  0.7
GUAN Est means Placebo 21.2  0.4 Guanfacine 14.5  0.4 Guanfacine 12.3  0.6
Obs means Placebo 21.1  0.6 Guanfacine 14.5  0.8 Guanfacine 11.6  0.9
DMPH Est means Placebo 21.2  0.4 Placebo 19.0  0.6 DMPH 12.8  0.7
Obs means Placebo 21.3  0.5 Placebo 19.6  0.7 DMPH 12.8  0.7
Hyperactive-Impulsive Subscale Estimated and Actual Mean Scores
Assigned
Group Estimated/Observed Current Med
Baseline
Mean  SE Current Med
Wk 4
Mean  SE Current Med
Wk 8
Mean  SE
COMB Est means Placebo 15.0  0.4 Guanfacine 9.6  0.5 Comb 7.2  0.8
Obs means Placebo 15.1  0.9 Guanfacine 10.3  0.8 Comb 7.3  0.7
GUAN Est means Placebo 15.0  0.4 Guanfacine 9.6  0.5 Guanfacine 7.5  0.8
Obs means Placebo 15.6  0.8 Guanfacine 9.0  0.8 Guanfacine 7.2  0.6
DMPH Est means Placebo 15.0  0.4 Placebo 12.7  0.6 DMPH 7.6  0.8
Obs means Placebo 14.3  0.8 Placebo 12.8  0.8 DMPH 7.6  0.6
Note: Assigned groups are final groups designated as COMB (guanfacine þ dexmethylphenidate), GUAN (guanfacine þ placebo), DMPH (placebo þ dexmethyl-
phenidate). Estimated means are values estimated from the mixed model for each arm at each time point based on the current medication status and accounting for
drift over time. Observed means are the raw values for each arm at each time point. Comb ¼ combination; Est ¼ estimated; Med ¼ medication; Obs ¼ observed;
SE ¼ standard error.
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